Skip to content

Upper Extremity Rehabilitation Using Robot and Botulinum Toxin

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02228863
Enrollment
348
Registered
2014-08-29
Start date
2014-03-31
Completion date
Unknown
Last updated
2014-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spasticity, Stroke

Keywords

Stroke, Spasticity

Brief summary

Concomitant use of botulinum toxin and robot would make better results regarding upper extremity function compared to robot, botulinum toxin, or no intervention.

Interventions

OTHEREarly Inmotion and Botox

Concomitant use of Inmotion and Botox from the baseline

OTHERBotox, then Inmotion

At baseline Botox injection and 4 weeks after Inmotion

OTHERInmotion, then Botox

Inmotion from the baseline, then Botox injection at 4 weeks after baseline

OTHERLate Inmotion and Botox

No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection

Sponsors

National Rehabilitation Center, Seoul, Korea
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hemiplegic patients secondary to first cerebrovascular accidents * Shoulder or Elbow flexor spasticity above or modified ashworth scale 1+ * Cognitively intact enough to understand and follow the instructions from the investigator

Exclusion criteria

* History of surgery of affected upper limb * Fracture of affected upper limb * Recent history of botulinum toxin injection within 6 months

Design outcomes

Primary

MeasureTime frame
Change of Fugl-Meyer AssessmentFugl-Meyer Assessment change from baseline at 8 weeks

Secondary

MeasureTime frameDescription
Spasticity of elbow and shoulder jointbaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baselineModified Ashworth scale of elbow and shoulder joint Modified Tardieu scale of elbow and shoulder joint
Medical research council scale of elbow and shoulder joint strengthbaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline
Painless range of motion of elbow and shoulder jointbaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline
numeric rating scale of pain of elbow and shoulder jointbaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline
Associated reaction rating scalebaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline
surface electromyography data from bilateral upper extremitiesbaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline
Behavioral activation system/behavioral inhition system scalebaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baselineIn terms of motivation
Kinematic dataBaseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baselineKinematic data from motion analysis (Vicon) Kinematic data from Inmotion
Fugl-Meyer AssessmentBaseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
Stroke impact scalebaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline
Beck's depression indexbaseline, 4 weeks, 8 weeks, and 12 weeks from baseline
Satisfaction about the interventionbaseline, 4 weeks after baseline, 8 weeks after baseline, 12 weeks after baseline
Adverse eventFrom baseline to 12 weeks from the baseline
Digit span testbaseline, 5days after Inmotion, 20 days after Inmotion.Digit span test(forward, backward) during baseline, 5 days of Inmotion, 20 days of Inmotion. The test was done at rest and with Inmotion trial
Controlled Oral Word Association Testbaseline, 5ays of Inmotion, 20 days of InmotionControlled Oral Word Association Test during baseline, 5 days of Inmotion, 20 days of Inmotion. The test was done at rest and with Inmotion trial

Countries

South Korea

Contacts

Primary ContactJoon-Ho Shin, MS
asfreelyas@gmail.com82-2-901-1884

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026